Supplementary Materials

The PDF file includes:

  • Methods
  • Fig. S1. Nerinetide does not affect the thrombolytic activity of alteplase (tPA) or TNK in human plasma pooled from 10 subjects.
  • Fig. S2. Nerinetide has a short half-life in humans.
  • Fig. S3. Nerinetide has a wide therapeutic range in a tMCAO model.
  • Fig. S4. Lodoxamide (0.6 mg/kg) administration 1 hour after stroke onset has no effect on infarct volume reduction or functional outcome in animals subjected to a 90-min tMCAO.
  • Table S1. Physiological parameters in nerinetide dose-response study in rats subjected to a 90-min tMCAO.
  • Table S2. Physiological parameters in the study evaluating lodoxamide and D-Tat-L-2B9c in rats subjected to tMCAO.
  • Table S3. Physiological parameters in the nerinetide dose-separation study in rats subjected to eMCAO.
  • Table S4. Physiological parameters in the D-Tat-L-2B9c study in rats subjected to eMCAO.
  • Table S5. Mortalities and replacements in the nerinetide dose-response study in rats subjected to a 90-min tMCAO.
  • Table S6. Mortalities and replacements in the study evaluating lodoxamide and D-Tat-L-2B9c in rats subjected to a 90-min tMCAO.
  • Table S7. Mortalities and replacements in the study evaluating dose-separation between nerinetide and alteplase infusion in rats subjected to eMCAO.
  • Table S8. Mortalities and replacements in the study evaluating the concurrent administration of D-Tat-L-2B9c and alteplase in rats subjected to eMCAO.
  • Legend for data file S1
  • References (35, 36)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: